Cassava Sciences Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Vanguard S&P 500 Growth Index Fund ETF trades at $81.92. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | VOOG | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.64 | $85.11 |
52-Week Low | $1.09 | $65.32 |
Enterprise Value | -$33.43M | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VOOG, the Vanguard S&P 500 Growth ETF, trades at $82.17, down 0.86% on the day. Technical indicators show a bullish trend with moving averages strongly supportive, while oscillators are neutral. The recent 1:6 stock split on April 21, 2026, enhanced share accessibility. Financial media sentiment is positive, highlighting its low expense ratio and strong long-term growth potential compared to peers.
The outlook remains favorable given its focus on S&P 500 growth stocks, particularly in technology. Key risks include high sector concentration and market volatility. Analyst consensus is bullish, with institutional interest supported by consistent performance. Upside potential hinges on sustained earnings growth from its tech-heavy holdings.
Trailing returns across standard periods
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →